| Requested procedure | Catheter ablation for persistent atrial fibrillation (CPT 93656) |
| Plan type | Commercial HMO |
| Denial basis | "Does not meet medical necessity. Conservative management options have not been exhausted." |
| P2P call scheduled | [Fictional — 2 days from brief delivery] |
| Payer reviewer | Medical director (specialty unknown — assume internal medicine or cardiology) |
| Brief turnaround | 24 hours |
The P2P is not only a clinical conversation — it is a criteria-evaluation exercise conducted verbally. The payer medical director is evaluating whether the request satisfies specific elements of the plan's coverage criteria for atrial fibrillation ablation. Understanding what they are looking for determines whether the call succeeds.
The reviewer is likely checking for:
Key insight: The most common reason P2P calls fail for ablation requests is that the treating physician describes the patient's symptoms and clinical course — which the reviewer already has from the chart — instead of mapping the clinical data to the specific criteria elements listed above. The reviewer is not asking "is this patient sick?" They are asking "does this case check the boxes?" This brief is designed to close that gap.
Below is the patient's clinical data organized by the criteria elements the reviewer is most likely evaluating — not by the chronological clinical story.
Talking point: "This patient has trialed four antiarrhythmic and rate-control agents over approximately 36 months. Two failed on efficacy, one caused symptomatic hypotension requiring discontinuation, and one caused thyroid toxicity requiring discontinuation on specialist recommendation. The pharmacologic pathway has been genuinely exhausted — not abandoned prematurely."
Talking point: "The symptom burden is not mild or intermittent. This patient has EHRA Class III symptoms with documented functional decline over three years, including occupational impact. The severity is documented across multiple visits, not a single subjective complaint."
Talking point: "The EF decline from 58% to 45% over two years suggests tachycardia-mediated cardiomyopathy — a recognized indication where ablation may be therapeutic, not merely palliative. Current guidelines support ablation in patients with heart failure and AFib. The LA size is within the eligible range."
"The patient hasn't tried dofetilide or sotalol. Has the full pharmacologic pathway really been exhausted?"
Dofetilide requires inpatient initiation with continuous telemetry monitoring due to QT-prolongation risk — it is not a simple next-step medication. More importantly, the patient has already failed or developed serious adverse effects on four agents: two rate-control medications (one failed efficacy, one caused hypotension) and two rhythm-control medications (one recurred, one caused thyroid toxicity). The criteria require adequate pharmacologic trial, not exhaustion of every conceivable agent regardless of risk profile. The clinical trajectory — 36 months, four agents, two serious adverse effects — represents a genuine and documented pharmacologic pathway failure.
"If the reviewer insists on an additional agent trial, ask: what specific medication would the reviewer recommend given this patient's documented hypotension on diltiazem, thyroid toxicity on amiodarone, and declining EF? The clinical rationale for not adding another agent in this context is a physician judgment that the risks of further pharmacologic experimentation now exceed the risks of proceeding to ablation — especially with the EF decline suggesting tachycardia-mediated cardiomyopathy."
"The EF is 45% — that's only mildly reduced. Is tachycardia-mediated cardiomyopathy really the diagnosis?"
The relevant clinical finding is not the absolute EF but the trajectory: a decline from 58% to 45% over two years, temporally correlated with persistent AFib and inadequate rate control. The patient has no other identified cause of cardiomyopathy (no coronary artery disease on prior cath, no valvular disease, no hypertensive cardiomyopathy). The cardiologist's documented assessment — "decline likely tachycardia-mediated" — is a clinical judgment supported by the exclusion of alternatives and the temporal relationship. Current guidelines recognize this as a population where ablation has demonstrated EF recovery.
"If EF continues to decline without intervention, the patient progresses toward symptomatic heart failure. Ablation at this stage — before further deterioration — is a proactive clinical decision, not a premature one. Waiting for worse EF before authorizing is a clinical risk the plan would need to justify."
"Can we try a cardioversion first to see if sinus rhythm is maintainable?"
The patient has persistent AFib of 36+ months duration. Cardioversion without ablation in persistent AFib has a documented recurrence rate exceeding 50–70% within 12 months, even with antiarrhythmic support — and this patient cannot tolerate the antiarrhythmics that would be required to maintain post-cardioversion rhythm. Cardioversion alone is not a durable treatment strategy for this patient. It would delay definitive therapy without changing the clinical trajectory.
Structure the call in this sequence — criteria elements first, clinical story second.
"I'm calling about a prior authorization for catheter ablation in a patient with persistent atrial fibrillation who has failed four antiarrhythmic and rate-control agents over 36 months, has EHRA Class III symptoms with documented functional and occupational decline, and has an EF that has dropped from 58% to 45% — suggesting tachycardia-mediated cardiomyopathy with no other identified etiology. I'd like to walk through the pharmacologic history, symptom burden, and cardiac assessment."
Present pharmacologic failure first (the specific drugs, specific durations, specific reasons for failure — not "we tried everything"). Then symptom burden (EHRA Class III, functional decline, occupational impact). Then cardiac assessment (EF trajectory, LA size, CHA₂DS₂-VASc, cardiomyopathy assessment).
Confirm CPT, facility, timeline, and whether any additional documentation is needed. Do not linger.
Ask the reviewer to specify which criteria element was not satisfied and what additional evidence would be required. Document the reviewer's name, the specific unmet element, and the stated requirement. This becomes the foundation for the Level 1 written appeal — now with a documented record of what the reviewer said the criteria required. Request the formal written denial with cited criteria.
Do not: Read the entire clinical history during the call. The reviewer has the chart. They need to hear the criteria-relevant evidence organized by the elements they are evaluating — not a retelling of 36 months of visits.
Want this level of reasoning on your own cases?